On January 16, 2026, Paul Badawi, the Chief Executive Officer of Sight Sciences (NASDAQ: SGHT), conducted a sale of 22,362 shares of the company’s common stock, as documented in a Form 4 filing submitted to the Securities and Exchange Commission. The shares were sold at a weighted average price of $6.62, generating proceeds totaling $148,036. The transaction’s sale prices spanned from $6.44 to $6.69 per share.
Following this transaction, Badawi retains direct ownership of 6,025,840 shares in Sight Sciences.
In parallel with this insider sale, Sight Sciences has released preliminary revenue estimates for the fourth quarter of 2025, projecting figures between $20.3 million and $20.4 million, indicative of an approximate 7% increase over the same quarter in the previous year.
Breaking down segment performance, the company's Surgical Glaucoma division is expected to contribute roughly $19.6 million to $19.7 million, reflecting a year-over-year growth of 5%. Meanwhile, revenues from the Dry Eye segment are estimated at $0.7 million—representing significant growth of about 130% compared to the prior period.
Market analysts have responded positively; Piper Sandler upgraded Sight Sciences’ stock rating from Neutral to Overweight and raised its price target from $5.00 to $9.00, citing optimism linked to the potential of the company’s TearCare product.
Additionally, the company reported encouraging results from three pivotal clinical studies focused on the OMNI device, which is designed to treat glaucoma. The studies indicated sustained reductions in intraocular pressure and decreased reliance on medication among patients.
Following an earnings report for the third quarter of 2025 that topped revenue expectations and prompted an uplift in full-year guidance, Needham maintained its Hold rating on the stock.
Regarding changes in the corporate leadership team, Sight Sciences appointed Alison Bauerlein as Chief Operating Officer and James Rodberg as Chief Financial Officer, effective November 5, 2025. Bauerlein, who joined the company in April 2023, previously co-founded Inogen and was instrumental in scaling that organization.